Posted by Michael Wonder on 26 Oct 2021
Bausch + Lomb and Clearside Biomedical announce FDA approval of Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular oedema Associated with Uveitis
25 October 2021 - Xipere is the first and only medicine to be approved in the United States for delivery via suprachoroidal injection, a method designed to facilitate targeted delivery of therapeutic agents to the retina and choroid.
Bausch + Lomb and Clearside Biomedical today announced that the U.S. FDA has approved Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular oedema associated with uveitis, a form of eye inflammation.
